Mizuho Markets Americas LLC Purchases 20,214 Shares of Danaher Corporation (NYSE:DHR)

Key Points

• Mizuho Markets Americas LLC increased its holdings in Danaher Corporation by 20.9% during the first quarter, bringing its total shares owned to 116,811, valued at approximately $23.95 million.
• Danaher Corporation's Chairman, Steven M. Rales, sold 1.25 million shares of the company for over $245 million, resulting in a significant decrease of 28.70% in his ownership stake.
• Analysts have mixed opinions on Danaher's stock, with a consensus rating of "Moderate Buy" and a price target range between $225.00 and $275.00.

Mizuho Markets Americas LLC increased its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 20.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 116,811 shares of the conglomerate's stock after buying an additional 20,214 shares during the quarter. Mizuho Markets Americas LLC's holdings in Danaher were worth $23,946,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. FAS Wealth Partners Inc. raised its position in Danaher by 20.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after purchasing an additional 1,639 shares during the last quarter. MGO One Seven LLC increased its stake in shares of Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after buying an additional 20,813 shares during the period. Asahi Life Asset Management CO. LTD. acquired a new stake in shares of Danaher in the 1st quarter valued at $539,000. Horizon Financial Services LLC increased its stake in shares of Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after buying an additional 8,160 shares during the period. Finally, EFG Asset Management Americas Corp. increased its stake in shares of Danaher by 13.1% in the 1st quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate's stock valued at $7,396,000 after buying an additional 4,191 shares during the period. Institutional investors own 79.05% of the company's stock.

Danaher Price Performance

NYSE:DHR traded up $3.56 during trading hours on Wednesday, reaching $209.28. 3,241,300 shares of the company were exchanged, compared to its average volume of 4,263,600. The business has a 50 day moving average of $198.95 and a 200 day moving average of $200.34. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The company has a market capitalization of $149.86 billion, a P/E ratio of 44.53, a P/E/G ratio of 2.79 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The company's quarterly revenue was up 3.4% on a year-over-year basis. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Royal Bank Of Canada reissued an "outperform" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. Jefferies Financial Group decreased their price objective on Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research note on Tuesday, April 22nd. Barclays reaffirmed an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. UBS Group decreased their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Finally, TD Cowen lifted their price objective on Danaher from $240.00 to $248.00 and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.